Suzhou Ribo Life Science Co., Ltd. is a biotechnology company specializing in the research, development, and industrialization of small nucleic acid drugs, particularly using RNA interference (RNAi) technology and oligonucleotide therapeutics. It focuses on treating cardiovascular, metabolic, renal, liver, and other chronic diseases through a vertically integrated platform that covers the full lifecycle from early R&D to commercialization, including proprietary technologies like the liver-targeted delivery platform RiboGalSTAR and chemical modification systems. The company advances a pipeline of siRNA drug candidates, such as those targeting thrombotic diseases, hypertriglyceridemia, hypercholesterolemia, hepatitis, and renal conditions, with several in clinical phases including Phase II and Phase I trials. Suzhou Ribo Life Science Co., Ltd. maintains R&D centers in Beijing and Suzhou in China, and an international center in Gothenburg, Sweden, supporting global clinical development and partnerships with multinational pharmaceutical companies. Founded in 2007 and headquartered in Kunshan, China, it plays a key role in pioneering oligonucleotide drugs for unmet medical needs in chronic disease management.